The GAP Foundation is joining together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to reduce the time, cost and risk of Alzheimer’s & Parkinson's clinical trials in order to speed innovative medicines to those with or at risk of Alzheimer’s & Parkinson's disease. GAP is a standing, global, trial-ready platform to drive quality, efficiency, equity and innovation in Alzheimer’s and Parkinson's Clinical Trials, seeking to reduce clinical testing cycle times by two years or more and to achieve greater trial populations. It is doing that by building large, well-characterized trial-ready cohorts, a network of certified high-performance clinical trial sites, and an adaptive proof-of-concept trial mechanism. Connect with us on our Facebook page, @GlobalALZPlatform, and on Twitter, @GAP_Foundation, where we share updates from our GAP-Network (GAP-Net) and from the volunteers that make it all possible.
Free account • No credit card • 5 profiles/day
The widely used Global Alzheimer's Platform Foundation email format is {first_initial}{last}@globalalzplatform.org (e.g. jsmith@globalalzplatform.org), which is used 75.00% of the time.
| Global Alzheimer's Platform Foundation Email Formats | Example Email Formats | Adoption |
|---|---|---|
| {first_initial}{last} | jsmith@globalalzplatform.org |
75.00%
|
| Other formats | — |
25%
|
Adoption = share of company emails using each format — not a verification or accuracy score.
OncoLens
Hospitals and Health Care • 11-50 employees • Atlanta, United States
Alzheimer's Treatment Centers Of America
Hospitals and Health Care • 2-10 employees • Dunwoody, United States
Modality.AI
Software Development • 11-50 employees • San Francisco, United States
Guardian Research Network
Hospitals and Health Care • 11-50 employees • Spartanburg, United States
AGA Clinical Trials
Hospitals and Health Care • 11-50 employees • Hialeah, United States
Ivy Brain Tumor Center
Hospitals and Health Care • 51-200 employees • Phoenix, United States
What is Global Alzheimer's Platform Foundation email format?
The widely used Global Alzheimer's Platform Foundation email format is {first_initial}{last} (e.g. jsmith@globalalzplatform.org) with 75.00% adoption across the company.
What is Global Alzheimer's Platform Foundation customer service number?
To contact Global Alzheimer's Platform Foundation customer service number in your country click here to find.
Who are the decision makers in Global Alzheimer's Platform Foundation?
The decision makers in Global Alzheimer's Platform Foundation are Douglas Beauregard, Jill Smith, Julie Sipchen, etc. Click to Find Global Alzheimer's Platform Foundation decision makers emails.
What is the Global Alzheimer's Platform Foundation (GAP Foundation)?
The Global Alzheimer's Platform Foundation (GAP Foundation) is a collaborative initiative that unites leading academic researchers, pharmaceutical companies, nonprofit organizations, and government entities worldwide. Its primary mission is to accelerate the development of new treatments for Alzheimer's disease by reducing the time, cost, and risk associated with clinical trials. By fostering partnerships and creating a robust network, the GAP Foundation aims to enhance research efforts and improve outcomes for patients and caregivers affected by Alzheimer's and related dementias.
How does GAP Foundation support clinical trials for Alzheimer's research?
The GAP Foundation supports clinical trials by providing a comprehensive network known as GAPNet, which connects researchers, trial sites, and patients. This network facilitates the recruitment of participants for clinical trials, streamlining the process and ensuring that trials are conducted efficiently. Additionally, the foundation offers resources and tools to help researchers design and implement trials, as well as access to data and best practices that can enhance the quality of research outcomes.
Who can participate in the clinical trials facilitated by the GAP Foundation?
Participation in clinical trials facilitated by the GAP Foundation is open to individuals diagnosed with Alzheimer's disease or related dementias, as well as healthy volunteers in some studies. Eligibility criteria vary depending on the specific trial, and potential participants are encouraged to consult with their healthcare providers or visit the GAP Foundation's website for information on ongoing trials and how to get involved.
What types of organizations can collaborate with the GAP Foundation?
The GAP Foundation welcomes collaboration from a diverse range of organizations, including academic institutions, pharmaceutical companies, nonprofit organizations, healthcare providers, and government agencies. By partnering with these entities, the GAP Foundation aims to create a comprehensive ecosystem that fosters innovation and accelerates the development of effective treatments for Alzheimer's disease.
How does the GAP Foundation ensure equality in Alzheimer's research?
The GAP Foundation is committed to promoting equality in Alzheimer's research by ensuring diverse representation in clinical trials and research initiatives. This includes actively seeking participants from various demographic backgrounds, including different ages, races, and socioeconomic statuses. The foundation also advocates for inclusive research practices that address the unique needs of underrepresented populations in the context of Alzheimer's disease and related dementias.
What resources does the GAP Foundation offer for individuals seeking information about Alzheimer's disease?
The GAP Foundation provides a wealth of resources for individuals seeking information about Alzheimer's disease, including educational materials, research updates, and access to clinical trial information. Their website features a dedicated section for patients and caregivers, offering guidance on navigating the complexities of Alzheimer's care, understanding treatment options, and finding support networks. Additionally, the foundation regularly hosts webinars and community events to raise awareness and share knowledge about Alzheimer's research and care.
